Table 2.
Cardiovascular events in patients with prostate cancer treated with degarelix, leuprorelin, goserelin or triptorelin
| Degarelix users n = 101 | Leuprorelin n = 3289 | Goserelin n = 4366 | Triptorelin n = 1325 | GnRH agonists (pooled) n = 8980 | |
|---|---|---|---|---|---|
| Patients with an incident cardio event after initiation of therapy | |||||
| Any cardiac event, n (%) | 7 (6.9) | 564 (17.1) | 844 (19.3) | 185 (14.0) | 1593 (17.7) |
| Relative risk (95% CI)a | – | 0.40 (0.197, 0.829) | 0.36 (0.175, 0.735) | 0.50 (0.240, 1.027) | 0.39 (0.191, 0.799) |
| p value | – | 0.0135 | 0.0051 | 0.0590 | 0.0101 |
| HF, n (%) | 1 (1.0) | 140 (4.3) | 196 (4.5) | 52 (3.9) | 388 (4.3) |
| Relative risk (95% CI)a | – | 0.23 (0.033, 1.646) | 0.22 (0.031, 1.558) | 0.25 (0.035, 1.806) | 0.23 (0.033, 1.615) |
| p value | – | 0.1441 | 0.1297 | 0.1703 | 0.1392 |
| MI, n (%) | 2 (2.0) | 80 (2.4) | 147 (3.4) | 24 (1.8) | 251 (2.8) |
| Relative risk (95% CI)a | – | 0.81 (0.203, 3.266) | 0.59 (0.148, 2.341) | 1.09 (0.262, 4.560) | 0.71 (0.179, 2.809) |
| p value | – | 0.7717 | 0.4513 | 0.9026 | 0.6238 |
| Arrhythmia, n (%) | 3 (3.0) | 308 (9.4) | 516 (11.8) | 115 (8.7) | 939 (10.5) |
| Relative risk (95% CI)a | – | 0.32 (0.104, 0.972) | 0.25 (0.082, 0.768) | 0.34 (0.111, 1.058) | 0.28 (0.093, 0.867) |
| p value | – | 0.0444 | 0.0154 | 0.0625 | 0.0271 |
| IHD, n (%) | 5 (4.9) | 264 (8.0) | 377 (8.6) | 63 (4.7) | 704 (7.8) |
| Relative risk (95% CI)a | – | 0.62 (0.260, 1.461) | 0.57 (0.243, 1.355) | 1.04 (0.428, 2.530) | 0.63 (0.268, 1.489) |
| p value | – | 0.2720 | 0.2048 | 0.9290 | 0.2934 |
| Time from initiation therapy to the first cardio event | |||||
| Mean, days (SD) | 244.9 (220.1) | 542.9 (572.0) | 613.7 (618.5) | 605.3 (502.3) | – |
| Median, days (IQR) | 206.0 (85.0–219.0) | 322.5 (137.0–751.0) | 415.0 (136.5–880.5) | 493.0 (215.0–853.0) | – |
CI confidence interval, CV cardiovascular, GnRH gonadotropin-releasing hormone, HF heart failure, IHD ischaemic heart disease, IQR interquartile range, MI myocardial infarction, SD standard deviation
aRelative risk with degarelix vs leuprorelin, goserelin, triptorelin and pooled GnRH agonists